Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BCAX vs MBX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MBX Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–1 Matrix Metrics)

MBX Overall Winner 6-Pillar Tally: BCAX 2 – 2 MBX (2 Tie) Matrix Metrics: BCAX 1 – 4 MBX

As of Nov 16, 2026, MBX Biosciences, Inc. (MBX) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). BCAX carries a Unified Composite Score of 52.1/100 (HOLD) at $9.58 (N/M Forward P/E, 0.0% operating margin), whereas MBX carries 44.9/100 (HOLD) at $53.54 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While BCAX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. MBX 44.9/100 HOLD), MBX captures the overall institutional head-to-head verdict (4–1 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile MBX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BCAX vs MBX
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.58
-4.39% 1D
Market Cap $671.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.41β · 184% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.1%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $11.85 · SMA50: $16.57
MBX NASDAQ Head-to-Head Winner
MBX Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$53.54
-4.29% 1D
Market Cap $2.7B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.58β · 66% Vol
Unified Composite Score
44.9 / 100 HOLD
Tech 42.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.8 · SMA20: $53.41 · SMA50: $55.62

6-Pillar Scorecard Institutional Category Breakdown (BCAX 2 – 2 MBX)

Columns: Metric · BCAX · MBX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale MBX
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $671.2M $2.7B
3. Profitability & Quality MBX
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -54.2% -33.7%
4. Balance Sheet & Cash Flow BCAX
Cash Generation (TTM) -$163M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $81M Net Cash $9.53 Book/Sh · -33.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BCAX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 102.7% (23rd %ile) 64.0% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BCAX (1) vs MBX (4)
Institutional Metric BCAX MBX Criterion Row Edge
Market Capitalization
Scale
$671.2M $2.7B Larger Scale MBX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-54.2% -33.7% Higher ROE MBX
52-Week Range Position
Momentum
7% ($8–$31) 62% ($23–$73) Stronger Trend MBX
Beta / 30D Volatility
Risk Regime
1.41β · 184% Vol 1.58β · 66% Vol Lower Realized Risk MBX
Unified Institutional Score
Composite Signal
52.1 / 100 (HOLD) 44.9 / 100 (HOLD) Higher Composite BCAX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$163M ($81M Net Cash) N/A ($9.53 Book/Sh · -33.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MBX +50.83 pp
BCAX: -42.91% · MBX: +7.92%
3M Horizon MBX +42.05 pp
BCAX: -61.56% · MBX: -19.51%
6M Horizon MBX +123.16 pp
BCAX: -50.34% · MBX: +72.82%
1Y Horizon MBX +155.25 pp
BCAX: -32.82% · MBX: +122.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs MBX. Trailing 12-month operating profitability (BCAX 0.0% vs MBX 0.0%) and valuation multiples (BCAX N/M vs MBX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BCAX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-54.2% · N/M
MBX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-33.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BCAX BREAKDOWN
93d in phase · OBV ACCUMULATION
Current IV 102.7%
IV Percentile 23rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact BCAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MBX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 64.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MBX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BCAX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $671.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MBX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.7B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BCAX vs MBX Key Questions & Quantitative Answers

As of Nov 16, 2026, MBX Biosciences, Inc. (MBX) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). BCAX carries a Unified Composite Score of 52.1/100 (HOLD) at $9.58 (N/M Forward P/E, 0.0% operating margin), whereas MBX carries 44.9/100 (HOLD) at $53.54 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While BCAX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. MBX 44.9/100 HOLD), MBX captures the overall institutional head-to-head verdict (4–1 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile MBX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MBX leads the Growth & Scale pillar: BCAX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MBX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BCAX generates N/A in USD-normalized revenue versus N/A for MBX. In operating R&D and SG&A reinvestment, BCAX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MBX.

BCAX and MBX trade at balanced relative valuation multiples. BCAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MBX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BCAX (-54.2% ROE) versus MBX (-33.7% ROE) capital efficiency.

In options market volatility and institutional positioning, BCAX carries 102.7% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.41β · 184% Vol realized risk). By comparison, MBX carries 64.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.58β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.